I don't understand why you talk about KAST like they're the gold standard of companies. From what I see, then have no revenue, only expenses. Their share price is currently $1.30, and IMO that is only because the own a patent. Look up their share structure. The float is super low at 269,544 (a/o July 18, 2016), however they also have authoriZed shares in the amount of 950,000,000- double that of vdrm. Call me crazy, but I'm gonna go with the DOCTOR instead of a PATENT ATTORNEY to run/own/lead a biopharmaceutical company.
Market Data 
Markets 
AI
